Oxygenta Pharma

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE102E01018
  • NSEID:
  • BSEID: 524636
INR
50.00
0.2 (0.4%)
BSENSE

Nov 20

BSE+NSE Vol: 52

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 798135,
    "name": "Oxygenta Pharma",
    "stock_name": "Oxygenta Pharma",
    "full_name": "Oxygenta Pharmaceutical Ltd",
    "name_url": "stocks-analysis/oxygenta-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "50.00",
    "chg": 0.2,
    "chgp": "0.4%",
    "dir": 1,
    "prev_price": "49.80",
    "mcapval": "184.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524636,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE102E01018",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "52 ",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/oxygenta-pharma-798135-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-4266792",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/OxygentaPharmac_mojoScore_4266792.png",
        "date": "2026-11-18 10:10:30",
        "description": "Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 September 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 18 November 2026, providing investors with the latest comprehensive analysis."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd Reports Flat Quarterly Performance Amid Margin Pressures",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/oxygenta-pharmaceutical-ltd-reports-flat-quarterly-performance-amid-margin-pressures-4258398",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/OxygentaPharmac_fintrenddot_4258398.png",
        "date": "2026-11-11 11:00:32",
        "description": "Oxygenta Pharmaceutical Ltd’s latest quarterly results for September 2026 reveal a marked shift in financial momentum, with the company’s growth trajectory flattening after a period of robust expansion. Despite a strong surge in net sales, rising interest expenses and a deteriorating financial trend score have weighed on investor sentiment, prompting a downgrade to a Strong Sell rating."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-4245442",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/OxygentaPharmac_mojoScore_4245442.png",
        "date": "2026-10-31 10:10:13",
        "description": "Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 September 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 31 October 2026, providing investors with the latest comprehensive view of the company’s position."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd Forms Death Cross Signalling Bearish Trend",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/oxygenta-pharmaceutical-ltd-forms-death-cross-signalling-bearish-trend-4243699",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/OxygentaPharmac_dealthcross_4243699.png",
        "date": "2026-10-29 18:00:52",
        "description": "Oxygenta Pharmaceutical Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average (DMA) crosses below the 200-DMA. This development signals a potential shift towards a sustained bearish trend, reflecting deteriorating momentum and long-term weakness in the stock’s price action."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-4207040",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/OxygentaPharmac_mojoScore_4207040.png",
        "date": "2026-09-28 10:10:37",
        "description": "Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 September 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 28 September 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Oxygenta Pharmaceutical Gains 3.14%: 2 Key Technical Signals Shape Weekly Momentum",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/oxygenta-pharmaceutical-gains-314-2-key-technical-signals-shape-weekly-momentum-4191412",
        "imagepath": "",
        "date": "2026-09-12 14:02:31",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>7 Sep:</strong> Stock opens at Rs.53.83 amid Sensex decline</p>\n                    <p><strong>8 Sep:</strong> Golden Cross formation signals potential bullish breakout; stock rises 3.05%</p>\n                    <p><strong>9 Sep:</strong> MarketsMOJO upgrades rating to Sell; stock dips 1.97%</p>\n                    <p><strong>11 Sep:</strong> Stock rebounds with 3.87% gain closing at Rs.55.88</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.54.18</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"sta..."
      },
      {
        "title": "Golden Cross Forms in Oxygenta Pharmaceutical Ltd — On a Day the Stock Gained 3.05%. What the Mixed Signals Mean",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/oxygenta-pharmaceutical-ltd-forms-golden-cross-signalling-potential-bullish-breakout-4186940",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/OxygentaPharmac_goldencross_4186940.png",
        "date": "2026-09-08 18:00:53",
        "description": "The 50-day moving average has crossed above the 200-day moving average for Oxygenta Pharmaceutical Ltd on 8 Sep 2026, signalling a golden cross. Yet, the stock’s 3.05% gain on the day contrasts with a mixed technical backdrop, where monthly momentum indicators remain bearish. This divergence invites a closer look at whether the golden cross stands as a reliable signal or a lone beacon amid conflicting data."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-4175945",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/OxygentaPharmac_mojoScore_4175945.png",
        "date": "2026-08-31 10:10:39",
        "description": "Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      }
    ],
    "total": 31,
    "sid": "798135",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/oxygenta-pharmaceutical-798135"
  },
  "announcements": [
    {
      "caption": "Un-Audited Financial Results For The Quarter And Half-Year Ended 30.09.2026.",
      "datetime": "10-Nov-2026",
      "details": "Un-audited Financial Results for the Quarter and Half-year ended 30.09.2026.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday I.E. 10Th November 2026.",
      "datetime": "10-Nov-2026",
      "details": "Outcome of Board Meeting held on Tuesday i.e. 10th November 2026.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for 1. Un-Audited Financial Results For The Quarter And Half Year Ended September 30 2026.",
      "datetime": "05-Nov-2026",
      "details": "",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Un-Audited Financial Results For The Quarter And Half-Year Ended 30.09.2026.

10-Nov-2026 | Source : BSE

Un-audited Financial Results for the Quarter and Half-year ended 30.09.2026.

Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday I.E. 10Th November 2026.

10-Nov-2026 | Source : BSE

Outcome of Board Meeting held on Tuesday i.e. 10th November 2026.

Board Meeting Intimation for 1. Un-Audited Financial Results For The Quarter And Half Year Ended September 30 2026.

05-Nov-2026 | Source : BSE

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available